Hanwha Plus 200 ETF (152100)
KRX SM KRX SM Primary Summary
152100 Chart
Hanwha Plus 200 ETF (152100) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Hanwha Plus 200 ETF ever had a stock split?
Hanwha Plus 200 ETF Profile
| KRX SM Exchange | United Kingdom Country |
Overview
Evgen Pharma plc stands as a trailblazer in clinical stage drug development, concentrating its pioneering efforts on crafting sulforaphane-based medical solutions aimed at the combat against cancer and inflammatory diseases. This endeavor is propelled forward through the innovative application of Sulforadex, a cutting-edge technology designed to stabilize sulforaphane, thereby facilitating its use in medical treatments. Founded in the year 2014 and establishing its headquarters in Nether Alderley, United Kingdom, Evgen Pharma has marked itself as a significant entity in the medical pharmaceutical landscape, continuously striving to push the boundaries of medical science for the betterment of patient care and treatment outcomes.
Products and Services
- SFX-01
- Out-licensing of Technology Services
Evgen Pharma's flagship product, SFX-01, is currently undergoing rigorous Phase II clinical trials, targeting metastatic breast cancer. This innovative treatment is a testament to the company's commitment to addressing some of the most challenging conditions in oncology. Furthermore, SFX-01 is being examined in Phase Ib/IIa clinical trials as a potential therapy for glioblastoma, an aggressive form of brain cancer. The versatility of SFX-01 is highlighted by its preclinical stage exploration for treating haematological malignancies and analogues, showcasing the significant potential of sulforaphane-based medicine in transforming cancer treatment paradigms.
Apart from its direct involvement in drug development, Evgen Pharma extends its innovation through the out-licensing of Sulforadex technology. This initiative enables other entities within the pharmaceutical and biotechnology sectors to leverage the stabilizing capabilities of Sulforadex for their sulforaphane-based therapeutic projects. Through this business strategy, Evgen Pharma not only amplifies the impact of its core technology but also fosters collaboration and advancement in the broader medical research community, contributing to the collective effort in fighting debilitating diseases.
